Allergan, Rugen Therapeutics collaborate to discover and develop novel therapies for ASD and OCD

November 25, 2015

Allergan plc, a leading global pharmaceutical company, and Rugen Therapeutics, a start-up biotechnology company focused on the development of novel treatments for unmet CNS disorders and funded by the F-Prime Biomedical Research Initiative, today announced that they have entered into an exclusive collaboration to support the discovery and development of novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD).

Previous Article
New research could lead to improved methods of detection for early-onset Parkinson's
New research could lead to improved methods of detection for early-onset Parkinson's

New research by biologists at the University of York could lead to improved methods of detection for early-...

Next Article
SkylineDx's MMprofiler receives CE-IVD certification
SkylineDx's MMprofiler receives CE-IVD certification

SkylineDx, today announced they have received CE-IVD registration from the European Competent Authority (Mi...